Kingdon Capital Management’s Gilead Sciences GILD Stock Holding History

Kingdon Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-58,668	Closed	-$4.64M	–	139
2016 Q3	$4.64M	Buy	+58,668	New	+$4.77M	0.21%	87
2015 Q2	–	Sell	-4,600	Closed	-$451K	–	147
2015 Q1	$451K	Buy	+4,600	New	+$467K	0.02%	147
2014 Q2	–	Sell	-88,790	Closed	-$6.29M	–	195
2014 Q1	$6.29M	Sell	88,790 -65,700	-43%	-$5.15M	0.32%	91
2013 Q4	$11.6M	Buy	154,490 +96,690	+167%	+$6.73M	0.53%	59
2013 Q3	$3.63M	Sell	57,800 -66,200	-53%	-$3.96M	0.18%	138
2013 Q2	$6.35M	Buy	+124,000	New	+$6.46M	0.38%	85

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Kingdon Capital Management's GILD Position: Q4 2016 in Review

Kingdon Capital Management sold out of Gilead Sciences (GILD) in Q4 2016, closing a stake of 58,668 shares — an estimated $4.64M sold.

Kingdon Capital Management first reported a position in GILD in Q2 2013 and held it in 6 quarters. The position peaked at $11.6M in Q4 2013. 1,574 funds tracked by Wall St. Rank hold GILD as of Q4 2016.

Kingdon Capital Management reported no remaining Gilead Sciences position as of Q4 2016 after selling out during the quarter.
Kingdon Capital Management sold 58,668 Gilead Sciences shares in Q4 2016, an estimated $4.64M.
Kingdon Capital Management first reported a position in Gilead Sciences in Q2 2013 and held it in 6 quarters.
Kingdon Capital Management's Gilead Sciences position peaked at $11.6M in Q4 2013.
1,574 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2016.

Based on Kingdon Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.